The combination of excessive reactive oxygen species (ROS) levels, neuroinflammation,
and pathogenic protein aggregation disrupt the homeostasis of brain microenvironment …

The treatment of Parkinson's disease (PD) is hampered by the blood-brain barrier (BBB). As
such, there is an urgent need for the development of a novel nanoplatform capable of …

Parkinson's disease (PD) is a progressive and chronic neurodegenerative disease of the
central nervous system. Early treatment for PD is efficient; however, long-term systemic …

The existence of the blood–brain barrier (BBB) and the complex inflammatory environment
in the brain are two major obstacles in the treatment of Parkinson's disease (PD). As a target …

Although evidence indicates that the abnormal accumulation of α‐synuclein (α‐syn) in
dopamine neurons of the substantia nigra is the main pathological feature of Parkinson's …

Despite the relative severity of Parkinson's disease (PD), to date, there has been only limited
success in preventing or treating this condition owing to the low permeability of the blood …

The blood–brain barrier (BBB) is a major limiting factor that prevents the treatment of
Parkinson's disease (PD). In the present study, MgOp@ PPLP nanoparticles are explored by …

Sustained and safe delivery of dopamine across the blood brain barrier (BBB) is a major
hurdle for successful therapy in Parkinson's disease (PD), a neurodegenerative disorder …

Mitochondrial dysfunction, which is directly involved in Parkinson's disease (PD), is
characterized by the production of reactive oxygen species (ROS) and aberrant energy …

Abstract Parkinson's disease (PD), one of common neurodegenerative diseases, afflicts
many elderly people lacking of effective treatment strategies. Rhynchophylline (RIN) is an …